Adrenomedullin promotes lung angiogenesis, alveolar development, and repair.
Bronchopulmonary dysplasia (BPD) and emphysema are significant global health problems at the extreme stages of life. Both are characterized by alveolar simplification and abnormal distal airspace enlargement due to arrested development or loss of alveoli, respectively. Both lack effective treatments. Mechanisms that inhibit distal lung growth are poorly understood. Adrenomedullin (AM), a recently discovered potent vasodilator, promotes angiogenesis and has protective effects on the cardiovascular and respiratory system. Its role in the developing lung is unknown. We hypothesized that AM promotes lung angiogenesis and alveolar development. Accordingly, we report that lung mRNA expression of AM increases during normal alveolar development. In vivo, intranasal administration of the AM antagonist, AM22-52 decreases lung capillary density (12.4 +/- 1.5 versus 18 +/- 1.5 in control animals; P < 0.05) and impairs alveolar development (mean linear intercept, 52.3 +/- 1.5 versus 43.8 +/- 1.8 [P < 0.05] and septal counts 62.0 +/- 2.7 versus 90.4 +/- 3.5 [P < 0.05]) in neonatal rats, resulting in larger and fewer alveoli, reminiscent of BPD. This was associated with decreased lung endothelial nitric oxide synthase and vascular endothelial growth factor-A mRNA expression. In experimental oxygen-induced BPD, a model of arrested lung vascular and alveolar growth, AM attenuates arrested lung angiogenesis (vessel density, 6.9 +/- 1.1 versus 16.2 +/- 1.3, P < 0.05) and alveolar development (mean linear intercept, 51.9 +/- 3.2 versus 44.4 +/- 0.7, septal counts 47.6 +/- 3.4 versus 67.7 +/- 4.0, P < 0.05), an effect in part mediated by inhibition of apoptosis. AM also prevents pulmonary hypertension in this model, as assessed by decreased right ventricular hypertrophy and pulmonary artery medial wall thickness. Our findings suggest a role for AM during normal alveolar development. AM may have therapeutic potential in diseases associated with alveolar injury.
Vadivel
Arul
A
Department of Pediatrics, Women and Children's Health Research Institute, University of Alberta, Edmonton, Canada.
Abozaid
Sameh
S
van Haaften
Tim
T
Sawicka
Monika
M
Eaton
Farah
F
Chen
Ming
M
Thébaud
Bernard
B
D000281:Administration, Intranasal; D053607:Adrenomedullin / Q000378:metabolism* / Q000627:therapeutic use*; D000818:Animals; D000831:Animals, Newborn; D006801:Humans; D008168:Lung / Q000187:drug effects / Q000473:pathology; D008855:Microscopy, Electron, Scanning; D008954:Models, Biological; D018919:Neovascularization, Physiologic; D010100:Oxygen / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism* / Q000627:therapeutic use*; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000378:metabolism*; D011651:Pulmonary Artery / Q000473:pathology; D051381:Rats; D014945:Wound Healing
D010446:Peptide Fragments; C104782:adrenomedullin (22-52); D053607:Adrenomedullin; D010100:Oxygen